MethylGene's MGCD290 misses in candidiasis Ph II

MethylGene Inc. (TSX:MYG) said a single oral dose of MGCD290 plus fluconazole missed the primary composite endpoint of improving therapeutic cure rate at day 28 vs. fluconazole alone in the Phase II (Trial 290-005) trial to treat mild to moderate vulvovaginal candidiasis. The company expects to report full data from the 171-patient trial next half. ...